Literature DB >> 9084497

Apobec-1 and apolipoprotein B mRNA editing.

L Chan1, B H Chang, M Nakamuta, W H Li, L C Smith.   

Abstract

Apolipoprotein (apo)B mRNA editing is a novel mechanism for the post-transcriptional regulation of gene expression in mammals. It consists of a C-->U conversion of the first base of the codon CAA, encoding glutamine-2153, to UAA, an in-frame stop codon, in apoB mRNA. Since its initial description in 1987, substantial progress has been made in the last few years on the mechanism of editing. Apobec-1, the catalytic component of the apoB mRNA editing enzyme complex, has been cloned. This article begins with an overview of the general biology of apoB mRNA editing. It then provides an in-depth analysis of the structure, evolution and possible mechanism of action of apobec-1. ApoB mRNA editing is the prototype of RNA editing in mammals. What we learn from apoB mRNA editing will be useful in our understanding of other examples of RNA editing in vertebrates which are being described with increasing frequency.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9084497     DOI: 10.1016/s0005-2760(96)00156-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  15 in total

1.  Transfer of plastid RNA-editing activity to novel sites suggests a critical role for spacing in editing-site recognition.

Authors:  M Hermann; R Bock
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

Review 2.  Message therapy: gene therapy that targets mRNA sequence and stability.

Authors:  K F Kozarsky; L A Couture
Journal:  Am J Hum Genet       Date:  1997-10       Impact factor: 11.025

3.  An AU-rich sequence element (UUUN[A/U]U) downstream of the edited C in apolipoprotein B mRNA is a high-affinity binding site for Apobec-1: binding of Apobec-1 to this motif in the 3' untranslated region of c-myc increases mRNA stability.

Authors:  S Anant; N O Davidson
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

4.  The role of the LDL receptor in apolipoprotein B secretion.

Authors:  J Twisk; D L Gillian-Daniel; A Tebon; L Wang; P H Barrett; A D Attie
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

5.  Apo E structure determines VLDL clearance and atherosclerosis risk in mice.

Authors:  C Knouff; M E Hinsdale; H Mezdour; M K Altenburg; M Watanabe; S H Quarfordt; P M Sullivan; N Maeda
Journal:  J Clin Invest       Date:  1999-06       Impact factor: 14.808

6.  APOBEC-1 and AID are nucleo-cytoplasmic trafficking proteins but APOBEC3G cannot traffic.

Authors:  Ryan P Bennett; Elie Diner; Mark P Sowden; Joshua A Lees; Joseph E Wedekind; Harold C Smith
Journal:  Biochem Biophys Res Commun       Date:  2006-09-18       Impact factor: 3.575

Review 7.  Transglycosylation: a mechanism for RNA modification (and editing?).

Authors:  George A Garcia; Jeffrey D Kittendorf
Journal:  Bioorg Chem       Date:  2005-02-23       Impact factor: 5.275

8.  Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA.

Authors:  A Mehta; M T Kinter; N E Sherman; D M Driscoll
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

9.  Regulatable liver expression of the rabbit apolipoprotein B mRNA-editing enzyme catalytic polypeptide 1 (APOBEC-1) in mice lacking endogenous APOBEC-1 leads to aberrant hyperediting.

Authors:  Martin Hersberger; Susannah Patarroyo-White; Xiaobing Qian; Kay S Arnold; Lucia Rohrer; Maureen E Balestra; Thomas L Innerarity
Journal:  Biochem J       Date:  2003-01-15       Impact factor: 3.857

10.  Dual action of neutral sphingomyelinase on rat hepatocytes: activation of cholesteryl ester metabolism and biliary cholesterol secretion and inhibition of VLDL secretion.

Authors:  Mariana Liza; Yolanda Chico; Olatz Fresnedo; Begoña Ochoa
Journal:  Lipids       Date:  2003-01       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.